The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases.
about
Cannabinoids in health and diseaseEffects of palmitoylation of Cys(415) in helix 8 of the CB(1) cannabinoid receptor on membrane localization and signallingGenetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice.A restricted population of CB1 cannabinoid receptors with neuroprotective activityPitfalls and solutions in assaying anandamide transport in cellsRegulation of neurite outgrowth by G(i/o) signaling pathways.Design and evaluation of a novel fluorescent CB2 ligand as probe for receptor visualization in immune cellsIncreased Contextual Fear Conditioning in iNOS Knockout Mice: Additional Evidence for the Involvement of Nitric Oxide in Stress-Related Disorders and Contribution of the Endocannabinoid SystemThree-Dimensional Biologically Relevant Spectrum (BRS-3D): Shape Similarity Profile Based on PDB Ligands as Molecular Descriptors.The gene expression profiles of induced pluripotent stem cells from individuals with childhood cerebral adrenoleukodystrophy are consistent with proposed mechanisms of pathogenesisRole of Lipids in Brain Injury and Diseases.Altered lipid metabolism in brain injury and disorders.The endocannabinoid system as a target for the treatment of motor dysfunction.Characterization of the endocannabinoid system in human neuronal cells and proteomic analysis of anandamide-induced apoptosis.The endocannabinoid system as a target for the treatment of neuronal damage.Molecular mechanisms and potential therapeutical targets in Huntington's disease.Cannabinoid receptor signalling in neurodegenerative diseases: a potential role for membrane fluidity disturbance.Prospects for cannabinoid therapies in basal ganglia disorders.Endocannabinoid signaling and its regulation by nutrients.The role of cannabinoids and leptin in neurological diseases.Crosstalk between dopamine D₂ receptors and cannabinoid CB₁ receptors regulates CNR1 promoter activity via ERK1/2 signaling.Functional characterization of putative cholesterol binding sequence (CRAC) in human type-1 cannabinoid receptor.Type-1 cannabinoid receptors colocalize with caveolin-1 in neuronal cells.Membrane-mediated action of the endocannabinoid anandamide on membrane proteins: implications for understanding the receptor-independent mechanism.Evaluation of phenoxybenzamine in the CFA model of pain following gene expression studies and connectivity mappingDynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients.Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.Whole-body biodistribution and radiation dosimetry of the cannabinoid type 2 receptor ligand [11C]-NE40 in healthy subjects.Neuroprotective activity of cannabinoid receptor-2 against oxidative stress and apoptosis in rat pups having experimentally-induced congenital hypothyroidism.Alteration in Fluidity of Cell Plasma Membrane in Huntington Disease Revealed by Spectral Phasor Analysis.Chemical Proteomic Analysis of Serine Hydrolase Activity in Niemann-Pick Type C Mouse Brain
P2860
Q24633884-6CF94BAC-4477-4432-A99D-E5D155AA028BQ28572239-D164B4C9-5071-4B8D-BA63-9EF4883AC66EQ30588621-2784B937-9645-4441-8A0A-0B329F7C2E95Q33730578-4FF27234-300E-4E0E-B5C1-12D1C5278C8CQ33993270-20F3F587-DAC4-4AE9-85F2-5676818A99FFQ34746354-8240A550-BD9C-49A7-B0A6-E995C33B4B7EQ35209538-43BDAF0D-30F1-4EA1-A15C-3B9A303C16F5Q36064473-34A1A3DD-80A9-4327-AC4B-C05DC7147913Q36199304-158A34EE-7CB7-4B2C-AD97-F119769AF221Q36632900-836E329D-8D97-425F-ADE6-3749BD51579CQ37051065-72B68C63-0ABA-44AB-91E0-8CFA63056776Q37254313-EFEA6EB3-7FBA-4123-A38C-BD52EA773FCBQ37394164-031010C0-FB87-4F34-B755-D0A33DB91FF4Q37447674-A4BC57E1-1AEB-44E0-9733-2C0DAB264BD5Q37709370-2FDC356D-576C-437D-B4EB-5F8E5D249E16Q37776087-511C64E5-F992-4E3D-B607-94AB4E06778FQ37842745-0DE07229-5D5E-48CA-837D-04B685FCB0B7Q37872326-C0D8BE58-FB05-4A1C-B5FE-F3777806DC27Q38206187-B63E316C-6FD3-4DC0-BD83-9A73F85C2D4CQ38423817-5DD2A97B-75D1-4039-A676-843807FECE84Q39109270-1993E124-B1AF-4D81-89D2-F2D057AFEAB8Q39610927-4088D8A1-EC2D-4DE8-B3D2-CED09CD7E8CDQ40090497-BF8EDC76-C9A8-43F1-A438-98A8D9B35803Q41894976-74C304C4-0C30-4DFB-B3D3-0C2126A2B4A0Q41906651-2BF8FFB1-7687-4EF9-9982-03047CA4B42CQ42167232-790248DF-743F-458A-B2A3-DF5C2C8F3572Q42478056-59E87C34-1F25-4FD9-9389-4C7D87BD27B1Q43441791-B619F6FF-B1F3-4754-8F93-FDF7112E791EQ47326858-1F0EF828-EAA7-41F9-93D0-4EDDB795F570Q49475422-4679191D-BF39-43DD-A0F8-0D2D32DAE83EQ57177300-A8A39A09-F586-4F8A-86BB-9EC807AFE715
P2860
The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The endocannabinoid pathway in ...... er neurodegenerative diseases.
@ast
The endocannabinoid pathway in ...... er neurodegenerative diseases.
@en
type
label
The endocannabinoid pathway in ...... er neurodegenerative diseases.
@ast
The endocannabinoid pathway in ...... er neurodegenerative diseases.
@en
prefLabel
The endocannabinoid pathway in ...... er neurodegenerative diseases.
@ast
The endocannabinoid pathway in ...... er neurodegenerative diseases.
@en
P921
P1476
The endocannabinoid pathway in ...... er neurodegenerative diseases.
@en
P2093
Mauro Maccarrone
Natalia Battista
P304
P356
10.1016/J.PNEUROBIO.2006.11.006
P577
2007-02-02T00:00:00Z